Company news
Edding Genor Group Holdings Limited news in 2026
Edding Genor Group Holdings Limited's news releases, calls and decks from 2026, newest first.
Next Day Disclosure Return
November 18, 2026
Continuing connected transactions and connected transaction in relation to (1) technology transfer and commercial production; and (2) equipment buyback
November 17, 2026
Next Day Disclosure Return
November 17, 2026
Next Day Disclosure Return
November 16, 2026
Voluntary announcement - IND approvals of GB268 from the NMPA for Phase Ib/II clinical trial in NSCLC and Phase II/iii clinical trial in BTC
November 16, 2026
Next Day Disclosure Return
November 13, 2026
Next Day Disclosure Return
November 12, 2026
Next Day Disclosure Return
November 11, 2026
Next Day Disclosure Return
November 10, 2026
Next Day Disclosure Return
November 9, 2026
Next Day Disclosure Return
November 6, 2026
Next Day Disclosure Return
November 4, 2026
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026
November 4, 2026
Next Day Disclosure Return
November 3, 2026
Next Day Disclosure Return
November 2, 2026
Next Day Disclosure Return
October 30, 2026
Next Day Disclosure Return
October 28, 2026
Next Day Disclosure Return
October 27, 2026
Voluntary announcement - first-in-human Phase I study data of GB268 presented at the esmo congress 2026
October 23, 2026
Next Day Disclosure Return
October 23, 2026
Next Day Disclosure Return
October 21, 2026
Next Day Disclosure Return
October 20, 2026
Next Day Disclosure Return
October 14, 2026
Next Day Disclosure Return
October 12, 2026
Voluntary announcement - IND approval from the NMPA for Phase II clinical trial of GB268 in colorectal cancer
October 11, 2026
Next Day Disclosure Return
October 8, 2026
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
October 7, 2026
Next Day Disclosure Return
September 30, 2026
Next Day Disclosure Return
September 29, 2026
Next Day Disclosure Return
September 28, 2026
2026 Interim Report
September 28, 2026
EDG Announced Phase Ib/II Clinical Trial of GB268 Obtained IND Approval by NMPA
July 2, 2026
Edding Genor Group Holdings: EDG Announced EDP167 has successfully completed the first subject dosing in its Phase II clinical trial
February 8, 2026